KR19990067353A - 외상으로 인한 뇌 손상 치룡용 의약제제 - Google Patents

외상으로 인한 뇌 손상 치룡용 의약제제 Download PDF

Info

Publication number
KR19990067353A
KR19990067353A KR1019980703360A KR19980703360A KR19990067353A KR 19990067353 A KR19990067353 A KR 19990067353A KR 1019980703360 A KR1019980703360 A KR 1019980703360A KR 19980703360 A KR19980703360 A KR 19980703360A KR 19990067353 A KR19990067353 A KR 19990067353A
Authority
KR
South Korea
Prior art keywords
acid
pharmaceutical preparation
tetrazol
tetrahydro
ethyl
Prior art date
Application number
KR1019980703360A
Other languages
English (en)
Korean (ko)
Inventor
브라이언 알. 파이크
Original Assignee
메이달 피터슨 존
에이치. 룬드벡 에이/에스
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 메이달 피터슨 존, 에이치. 룬드벡 에이/에스 filed Critical 메이달 피터슨 존
Publication of KR19990067353A publication Critical patent/KR19990067353A/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
KR1019980703360A 1995-11-06 1996-11-05 외상으로 인한 뇌 손상 치룡용 의약제제 KR19990067353A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DK1232/95 1995-11-06
DK123295 1995-11-06
PCT/DK1996/000458 WO1997017074A1 (en) 1995-11-06 1996-11-05 Treatment of traumatic brain injury

Publications (1)

Publication Number Publication Date
KR19990067353A true KR19990067353A (ko) 1999-08-16

Family

ID=8102484

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019980703360A KR19990067353A (ko) 1995-11-06 1996-11-05 외상으로 인한 뇌 손상 치룡용 의약제제

Country Status (18)

Country Link
EP (1) EP0866706A1 (de)
JP (1) JPH11514654A (de)
KR (1) KR19990067353A (de)
AU (1) AU706594B2 (de)
BG (1) BG63150B1 (de)
BR (1) BR9611396A (de)
CA (1) CA2234824A1 (de)
CZ (1) CZ287441B6 (de)
EA (1) EA000531B1 (de)
HU (1) HUP9901051A2 (de)
IS (1) IS4726A (de)
NO (1) NO982036L (de)
NZ (1) NZ321546A (de)
PL (1) PL326490A1 (de)
SK (1) SK58198A3 (de)
TR (1) TR199800801T2 (de)
WO (1) WO1997017074A1 (de)
ZA (1) ZA969320B (de)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR013096A1 (es) * 1997-07-01 2000-12-13 Lundbeck & Co As H Sal de adicion de acido maleico de 5-(2-etil-2-h-tetrazol-5-il)-1-metil- 1,2,3,6-tetrahidropiridina, composicion farmaceutica que la contiene, su usoen terapia y metodo de preparacion de la misma.
EP2258358A3 (de) 2005-08-26 2011-09-07 Braincells, Inc. Neurogenese mit Acetylcholinesterasehemmer
EP2275095A3 (de) 2005-08-26 2011-08-17 Braincells, Inc. Neurogenese durch modulation des Muscarinrezeptors
JP2009512711A (ja) 2005-10-21 2009-03-26 ブレインセルス，インコーポレイティド Ｐｄｅ阻害による神経新生の調節
CA2625210A1 (en) 2005-10-31 2007-05-10 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
WO2007134136A2 (en) 2006-05-09 2007-11-22 Braincells, Inc. Neurogenesis by modulating angiotensin
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
WO2010099217A1 (en) 2009-02-25 2010-09-02 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8714789D0 (en) * 1987-06-24 1987-07-29 Lundbeck & Co As H Heterocyclic compounds
US5328925A (en) * 1989-02-22 1994-07-12 Novo Nordisk A/S Piperidine compounds and their use
IE922270A1 (en) * 1991-07-26 1993-01-27 Akzo Nv Pyrazole derivatives
US5330994A (en) * 1992-03-24 1994-07-19 Warner-Lambert Company Tetrahydropyridine isoxazoline derivatives

Also Published As

Publication number Publication date
CZ287441B6 (en) 2000-11-15
JPH11514654A (ja) 1999-12-14
TR199800801T2 (xx) 1998-08-21
MX9803432A (es) 1998-09-30
IS4726A (is) 1998-04-27
CA2234824A1 (en) 1997-05-15
NO982036D0 (no) 1998-05-05
BG102480A (en) 1999-01-29
AU7490096A (en) 1997-05-29
SK58198A3 (en) 1998-10-07
NZ321546A (en) 2000-12-22
BR9611396A (pt) 1999-07-13
ZA969320B (en) 1997-05-30
EA000531B1 (ru) 1999-10-28
HUP9901051A2 (hu) 2000-03-28
CZ138998A3 (cs) 1998-10-14
WO1997017074A1 (en) 1997-05-15
PL326490A1 (en) 1998-09-28
AU706594B2 (en) 1999-06-17
EA199800434A1 (ru) 1998-10-29
BG63150B1 (bg) 2001-05-31
NO982036L (no) 1998-06-25
EP0866706A1 (de) 1998-09-30

Similar Documents

Publication Publication Date Title
KR100197452B1 (ko) 구토 치료를 위한 nk-1 수용체 길항제 및 5ht3 수용체 길항제
RU2414904C2 (ru) ЗАЩИТНОЕ СРЕДСТВО ДЛЯ НЕЙРОНА СЕТЧАТКИ, СОДЕРЖАЩЕЕ В КАЧЕСТВЕ АКТИВНОГО КОМПОНЕНТА ПРОИЗВОДНОЕ ПРОСТАГЛАНДИНА F2α
SK282403B6 (sk) 2,4-Disulfonyl-alfa-fenyl-terc-butylnitrón alebo jeho farmaceuticky prijateľná soľ, farmaceutický prostriedok s ich obsahom a ich použitie
JPH07509456A (ja) ２型糖尿病および肥満の治療および予防のための１，３−ジシクロプロピメチル−８−アミノ−キサンチンの使用
US6297262B1 (en) Treatment of schizophrenia and psychosis
SK170999A3 (en) Compositions for treating and preventing arterial thrombosis and use of a factor xa inhibitor on its own and/or combined with a platelet antiaggregating agent
JPH10505823A (ja) 脱髄性及び髄鞘形成障害性疾患を抑制する方法
KR950010148B1 (ko) 중독증 치료용 의약품
EP0275668B1 (de) Verwendung von Ketonderivaten zur Behandlung von Bewusstseinsstörungen
KR19990067353A (ko) 외상으로 인한 뇌 손상 치룡용 의약제제
US20030022925A1 (en) Derivatives of aryl (or heteroaryl) azolylcarbinoles for the treatment of urinary incontinence
KR20020001850A (ko) 기분장애, 적응장애 또는 혼재성 불안우울증의 치료 또는예방에 사용되는 의약의 제조를 위한 사레듀턴트 및 그의제약상 허용되는 염의 용도
US4312879A (en) Clonidine and lofexidine as antidiarrheal agents
EA022711B1 (ru) Комбинация дибромида 1,12-додекаметилен-бис-[4-метил-5-(2-гидроксиэтил)тиазолия] и артесуната для лечения тяжелой формы малярии
AU2001262741B2 (en) Medicines for the prevention and treatment of neurodegenerative diseases
JP3066561B2 (ja) 近視予防・治療剤
CA2453256A1 (en) Diphenhydramine tannate compositions and methods of use
US4363809A (en) Organic compounds
KR20110084514A (ko) 피리딘-3-카르발데히드 ｏ-(피페리딘-1-일-프로필)-옥심 유도체를 유효 성분으로서 함유하는 망맥락막 변성 질환의 치료제
WO2002013830A1 (fr) Inhibiteurs de la production de cytokines
CN1207039A (zh) 创伤性脑损伤的治疗
US3743746A (en) Process of treating peptic ulcer with a non-anticholinergic agent
WO1998005207A1 (en) Method for treating excessive aggression
PT87954B (pt) Processo para a preparacao de composicoes farmaceuticas contendo derivados de dioxopiperidina, com efeito antipsicotico
SK279730B6 (sk) Iazínu a jehofarmaceuticky a veterinárne prijateľn

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
E902 Notification of reason for refusal
E601 Decision to refuse application